23andMe Holding Co. Stock News

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q3 2022 Results - Earnings Call Transcript

There are a few different ways to invest in this sector, but will it be a winner in 2022?

Penny stocks can rise quickly on relatively small catalysts, making them a great gamble. Here are a few that should rise.

Are these household stocks under $5 on your watch list in 2022? The post 10 Top Penny Stocks To Buy Under $5 That Are Household Names appeared first on Penny Stocks to Buy, Picks, News and Information

Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021. T

23andMe Holding Co - Class A (ME) shares closed today at 1.1% above its 52 week low of $6.09, giving the company a market cap of $577M. The stock is currently down 7.5% year-to-date, down 46.0% over the past 12 months, and down 37.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 17.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8.2% The company's stock price performance over the past 12 months lags the peer average by 268.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

These smaller healthcare companies all have 10x potential for investors.

These two companies have massive growth opportunities and have declined sharply in recent months.

With these kinds of resources, these companies are becoming less-risky investments.

The company reported disappointing earnings results and has fallen victim to the recent sell-off in high-growth stocks.

Her genetics testing company is the latest to flounder after going public via SPAC.

23andMe recently reported quarterly results which held no major surprises as the company continues to build out its DNA-based reports available to consumers.

Last week's good news for the genetic data miner wasn't as good as it looked.

Anne Wojcicki, 23andme CEO, joins 'Closing Bell' to discuss its second quarter earnings report and what's driving growth for the company long-term.

23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?